Advertisement

Topics

FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study

09:27 EDT 9 Aug 2017 | Speciality Pharma Journal

SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive topline results from the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). Pamrevlumab is a proprietary, first-in-class, anti-connective tissue growth factor (CTGF) antibody being evaluated in fibrotic disease and …

Original Article: FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study

NEXT ARTICLE

More From BioPortfolio on "FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...